Bandaram pharma packtech Limited has announced key changes to its Board of Directors following a meeting held on 30.01.2026. The pharmaceutical packaging company made strategic appointments and accepted a resignation that will reshape its board composition.

Board Meeting Outcomes

The Board of Directors convened on Friday, 30.01.2026 at 05:10 p.m. at the company's registered office located at Oxford Towers, Old Airport Road, Kodihalli, Bangalore. The meeting, which concluded at 5:40 p.m., addressed critical governance matters under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

New Director Appointment Details

Mr. Eswar Reddy Putturu has been appointed as an Additional Director in the Non-Executive Independent category, subject to shareholder approval. His appointment is for a period of 5 years effective from 30.01.2026.

Professional Background

Mr. Putturu brings significant expertise to the board with his MBA in Finance & Marketing. His professional profile highlights:

• Expertise in marketing banking products and financial analysis
• Excellence in customer acquisition and relationship management
• Experience in delivering tailored financial solutions
• Focus on aligning business growth with customer needs

Director Resignation

Mrs. Priyanka Agarwal submitted her resignation from the position of Non-Executive Independent Director, citing personal reasons. Her resignation became effective from the close of business hours on 30.01.2026.

Other Directorships

At the time of her resignation, Mrs. Agarwal held directorship positions in:

• Midland Polymers Limited
• Cura Technologies Limited

In her resignation letter, Mrs. Agarwal confirmed that there were no material reasons for her resignation beyond the personal reasons mentioned. She expressed gratitude to her board colleagues and wished the company success in its endeavors.

Regulatory Compliance

The company has fulfilled all disclosure requirements under SEBI regulations, providing comprehensive details in Annexure-A as mandated by Part A of Schedule III and Regulation 30. The announcement was signed by Deepak Reddy B, Chairman and Managing Director (DIN: 07074102), ensuring proper corporate governance protocols were followed throughout the process.

Bandaram Pharma Packtech Limited , formerly known as Shiva Medicare Limited, has reported a net loss of Rs. 34.74 lakhs for the quarter ended September 30, 2025 (Q2 FY26), according to the company's latest financial results. This marks a significant downturn from the profit of Rs. 67.19 lakhs recorded in the same quarter of the previous year.

Revenue Decline

The company's standalone revenue from operations saw a substantial decrease, falling to Rs. 32.93 lakhs in Q2 FY26 from Rs. 316.61 lakhs in the corresponding quarter of the previous year. This represents a year-on-year decline of approximately 89.6% in revenue.

Financial Performance Overview

Here's a breakdown of the key financial metrics for Q2 FY26:

Expense Management

Despite the significant drop in revenue, Bandaram Pharma Packtech managed to reduce its total expenses by 75.8% year-on-year, from Rs. 283.53 lakhs in Q2 FY25 to Rs. 68.50 lakhs in Q2 FY26. However, this reduction in expenses was not sufficient to offset the sharp decline in revenue.

Half-Yearly Performance

For the six months ended September 30, 2025, the company reported:

• Total income of Rs. 109.50 lakhs, down from Rs. 588.76 lakhs in the same period last year
• Net loss of Rs. 61.63 lakhs, compared to a profit of Rs. 8.22 lakhs in the previous year

Consolidated Results

On a consolidated basis, the company fared slightly better:

• Q2 FY26 consolidated revenue stood at Rs. 1,372.48 lakhs, up from Rs. 710.83 lakhs in Q2 FY25
• Consolidated net profit for Q2 FY26 was Rs. 6.02 lakhs, though lower than the Rs. 67.19 lakhs reported in Q2 FY25

Balance Sheet Highlights

As of September 30, 2025, Bandaram Pharma Packtech reported:

• Total assets of Rs. 1,663.63 lakhs, down from Rs. 1,920.97 lakhs as of March 31, 2025
• Total equity (including share capital and other equity) of Rs. 1,148.66 lakhs, compared to Rs. 1,210.25 lakhs at the end of the previous fiscal year

The financial results indicate a challenging quarter for Bandaram Pharma Packtech, with a significant decline in revenue and a shift from profit to loss in the standalone results. However, the consolidated performance shows some resilience with increased revenue, albeit with reduced profitability compared to the previous year.